Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays.

Annals of laboratory medicine - 1 May 2024

Lee Jee-Soo, Cho Eun Hye, Kim Boram, Hong Jinyoung, Kim Young-Gon, Kim Yoonjung, Jang Ja-Hyun, Lee Seung-Tae, Kong Sun-Young, Lee Woochang, Shin Saeam, Song Eun Young

Abstract excerpt

Circulating tumor DNA (ctDNA) has emerged as a promising tool for various clinical applications, including early diagnosis, therapeutic target identification, treatment response monitoring, prognosis evaluation, and minimal residual disease detection. Consequently, ctDNA assays have been incorporated into clinical practice. In this review, we offer an in-depth exploration of the clinical implementation of ctDNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Neoplasm, Residual

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 38221747
DOI: 10.3343/alm.2023.0389
PMCID: PMC10813828

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays.PMID 38221747Read ↗

Revolution of Circulating Tumor DNA: From Bench Innovations to Bedside ImplementationsSemantic proximity Read ↗

Circulating Tumor DNA as Biomarkers for Cancer DetectionSemantic proximity Read ↗

Clinical Circulating Tumor DNA Testing for Precision Oncology.Semantic proximity Read ↗

Liquid biopsy: Comprehensive overview of circulating tumor DNA (Review)Semantic proximity Read ↗

Circulating Tumor DNA Assays in Clinical Cancer ResearchSemantic proximity Read ↗

Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.Semantic proximity Read ↗

Toward liquid biopsies in cancer treatment: application of circulating tumor DNASemantic proximity Read ↗

Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applicationsSemantic proximity Read ↗

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint ReviewSemantic proximity Read ↗

Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncologySemantic proximity Read ↗

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.Semantic proximity Read ↗

Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoringSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.